Orgenesis (OTCMKTS:ORGS) announced its quarterly earnings data on Monday. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.26), Fidelity Earnings reports. The company had revenue of $7.76 million for the quarter, compared to the consensus estimate of $6.38 million.
Shares of OTCMKTS:ORGS traded down $0.14 during midday trading on Tuesday, hitting $4.66. The company had a trading volume of 17,861 shares, compared to its average volume of 29,595. Orgenesis has a 12-month low of $3.78 and a 12-month high of $9.25. The business has a fifty day simple moving average of $4.47.
Separately, Zacks Investment Research upgraded shares of Orgenesis from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th.
Orgenesis Inc is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products.
Featured Article: Leveraged Buyout (LBO)
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.